- Home
- GECC vs RPID Comparison
GECC vs RPID Comparison
Compare GECC & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- RPID
- Stock Information
- Founded
- GECC 2016
- RPID 2006
- Country
- GECC United States
- RPID United States
- Employees
- GECC N/A
- RPID N/A
- Industry
- GECC Finance: Consumer Services
- RPID Medical Specialities
- Sector
- GECC Finance
- RPID Health Care
- Exchange
- GECC Nasdaq
- RPID Nasdaq
- Market Cap
- GECC 122.4M
- RPID 138.9M
- IPO Year
- GECC N/A
- RPID 2021
- Fundamental
- Price
- GECC $10.80
- RPID $3.63
- Analyst Decision
- GECC
- RPID Buy
- Analyst Count
- GECC 0
- RPID 1
- Target Price
- GECC N/A
- RPID $8.00
- AVG Volume (30 Days)
- GECC 24.8K
- RPID 81.8K
- Earning Date
- GECC 07-31-2025
- RPID 08-01-2025
- Dividend Yield
- GECC 14.00%
- RPID N/A
- EPS Growth
- GECC N/A
- RPID N/A
- EPS
- GECC 0.42
- RPID N/A
- Revenue
- GECC $42,909,000.00
- RPID $29,645,000.00
- Revenue This Year
- GECC $32.54
- RPID $18.54
- Revenue Next Year
- GECC N/A
- RPID $20.55
- P/E Ratio
- GECC $25.87
- RPID N/A
- Revenue Growth
- GECC 18.13
- RPID 28.36
- 52 Week Low
- GECC $8.87
- RPID $0.58
- 52 Week High
- GECC $11.39
- RPID $4.04
- Technical
- Relative Strength Index (RSI)
- GECC 57.57
- RPID 58.15
- Support Level
- GECC $10.28
- RPID $3.33
- Resistance Level
- GECC $10.60
- RPID $3.77
- Average True Range (ATR)
- GECC 0.25
- RPID 0.24
- MACD
- GECC 0.03
- RPID -0.01
- Stochastic Oscillator
- GECC 80.33
- RPID 81.82
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.